Literature DB >> 16982330

Cytotoxic and biochemical effects of 3,3',4,4',5,5'-hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells.

Zsuzsanna Horvath1, Marek Murias, Philipp Saiko, Thomas Erker, Norbert Handler, Sibylle Madlener, Walter Jaeger, Michael Grusch, Monika Fritzer-Szekeres, Georg Krupitza, Thomas Szekeres.   

Abstract

OBJECTIVE: Resveratrol (3,4',5,-trihydroxystilbene, RV), an ingredient of wine, is an inhibitor of the proliferation-linked enzyme ribonucleotide reductase (RR) and shows a broad spectrum of cytotoxic effects against human cancer cells. In order to enhance these effects, we introduced additional hydroxyl moieties into the molecule. In the present study, the activity of a novel RV analog, 3,3',4,4',5,5'-hexahydroxystilbene (M8), was investigated in HL-60 human promyelocytic leukemia cells.
METHODS: Cytotoxicity of M8 alone or in combination with Ara-C was assessed employing growth inhibition assays. Effects of M8 on nucleoside triphosphates (NTPs) and deoxynucleoside triphosphates (dNTPs) were examined by HPLC. The apoptotic potential of M8 and RV was compared using a specific double-staining method and inhibition of TNF-alpha-induced activation of NF-kappaB was studied. Cell-cycle distribution was analyzed by FACS.
RESULTS: Addition of ascorbic acid decreased the IC(50) value of M8 from 6.25 microM to 2 microM. M8 depleted dATP and dTTP pools to 41% and 21% of control values, whereas dCTP pools increased to 199% of untreated controls. In addition, TTP, ATP, CTP, and GTP concentrations were decreased while UTP concentrations increased. M8 induced apoptosis at concentrations significantly lower than RV and could remarkably inhibit the activation of NF-kappaB. M8 arrested cells in the S phase of the cell cycle while depleting cells in the G2-M phase and exhibited synergistic combination effects when applied simultaneously with Ara-C.
CONCLUSION: Due to these promising results, this novel polyhydroxylated stilbene derivative might become an additional option for the treatment of leukemia and therefore deserves further preclinical and in vivo testing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16982330     DOI: 10.1016/j.exphem.2006.05.018

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  9 in total

Review 1.  Resveratrol and resveratrol analogues--structure-activity relationship.

Authors:  Thomas Szekeres; Monika Fritzer-Szekeres; Philipp Saiko; Walter Jäger
Journal:  Pharm Res       Date:  2010-03-16       Impact factor: 4.200

2.  Multifactorial anticancer effects of digalloyl-resveratrol encompass apoptosis, cell-cycle arrest, and inhibition of lymphendothelial gap formation in vitro.

Authors:  S Madlener; P Saiko; C Vonach; K Viola; N Huttary; N Stark; R Popescu; M Gridling; N T-P Vo; I Herbacek; A Davidovits; B Giessrigl; S Venkateswarlu; S Geleff; W Jäger; M Grusch; D Kerjaschki; W Mikulits; T Golakoti; M Fritzer-Szekeres; T Szekeres; G Krupitza
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

3.  Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772).

Authors:  P Heffeter; A Popovic-Bijelic; P Saiko; R Dornetshuber; U Jungwirth; N Voevodskaya; D Biglino; M A Jakupec; L Elbling; M Micksche; T Szekeres; B K Keppler; A Gräslund; W Berger
Journal:  Curr Cancer Drug Targets       Date:  2009-08-01       Impact factor: 3.428

4.  [Resveratrol and newly synthetized resveratrol analogs in therapy of prostate carcinoma].

Authors:  B Djavan; S Marihart; F Kuehhas; M Rom; A Partin; J Schalken; T Sekeres
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

5.  Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells.

Authors:  Philipp Saiko; Geraldine Graser; Benedikt Giessrigl; Marie-Thérèse Steinmann; Heike Schuster; Andreas Lackner; Michael Grusch; Georg Krupitza; Walter Jaeger; Venkateswarlu Somepalli; Trimurtulu Golakoti; Monika Fritzer-Szekeres; Thomas Szekeres
Journal:  Invest New Drugs       Date:  2013-08-14       Impact factor: 3.850

6.  Resveratrol and its synthetic derivatives exert opposite effects on mesothelial cell-dependent angiogenesis via modulating secretion of VEGF and IL-8/CXCL8.

Authors:  Justyna Mikuła-Pietrasik; Angelika Kuczmarska; Małgorzata Kucińska; Marek Murias; Marcin Wierzchowski; Marek Winckiewicz; Ryszard Staniszewski; Andrzej Bręborowicz; Krzysztof Książek
Journal:  Angiogenesis       Date:  2012-03-27       Impact factor: 9.596

Review 7.  Potential of the dietary antioxidants resveratrol and curcumin in prevention and treatment of hematologic malignancies.

Authors:  Mareike Kelkel; Claus Jacob; Mario Dicato; Marc Diederich
Journal:  Molecules       Date:  2010-10-12       Impact factor: 4.411

8.  Synthetic resveratrol analogue, 3,3',4,4',5,5'-hexahydroxy-trans-stilbene, accelerates senescence in peritoneal mesothelium and promotes senescence-dependent growth of gastrointestinal cancers.

Authors:  Justyna Mikuła-Pietrasik; Patrycja Sosińska; Marcin Wierzchowski; Katarzyna Piwocka; Krzysztof Książek
Journal:  Int J Mol Sci       Date:  2013-11-14       Impact factor: 5.923

Review 9.  Therapeutic Versatility of Resveratrol Derivatives.

Authors:  Waqas Nawaz; Zhongqin Zhou; Sa Deng; Xiaodong Ma; Xiaochi Ma; Chuangang Li; Xiaohong Shu
Journal:  Nutrients       Date:  2017-10-29       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.